Lisdexamfetamine

Generic Name: Lisdexamfetamine

Brand Names: Vyvanse

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₅N_₃O

CAS Number: 608137-32-2

Unique Ingredient Identifier: H645GUL8KJ

Background: Lisdexamfetamine is a prodrug of dextroamphetamine, a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space.

Indication: Lisdexamfetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients six years and older. It is also indicated to treat moderate to severe binge eating disorder (BED) in adults. It is approved for use in the US and Canada.

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Moderate Binge Eating Disorder (BED), Severe Binge Eating Disorder (BED)

Associated Therapies: -

Clinical Trials

Athletes' ADHD, anxiety meds might increase heat stroke risk

Athletic trainer Kenya Moore noticed a player's disorientation after switching ADHD meds, leading to heat stroke. Experts warn that medications for ADHD, anxiety, and depression elevate heat stroke risk in athletes, calling for more research. Heat illness diagnoses and deaths have risen with global temperatures, with stimulants potentially increasing risk by constricting blood vessels and inhibiting sweating. Awareness and precautions are crucial, especially as mental health medication use rises.

additudemag.com

4 months ago

Vyvanse Shortage Update: DEA OKs Expanded Production of the ADHD Medication

DEA allows increased production of Vyvanse to address ADHD and BED treatment shortages, with 25% for domestic and 75% for foreign demand. Despite FDA approval for generic Vyvanse production, shortages persist due to active ingredient issues. DEA's quota-setting process faces criticism for causing shortages, prompting consideration of more transparent methods. Vyvanse remains the most popular stimulant among ADDitude survey respondents.

clinicaladvisor.com

4 months ago

Amid Shortages, US Allows Expanded Production of ADHD Drug Vyvanse

The DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% to address ongoing ADHD drug shortages, with a 13,478-pound increase including 3434 pounds for domestic and 10,313 pounds for foreign demand.

drugs.com

4 months ago

Amid Shortages, U.S. Allows Expanded Production of ADHD Drug Vyvanse

The U.S. DEA approved Takeda Pharmaceuticals to increase Vyvanse production by 24% due to ongoing ADHD drug shortages, with 13,478 pounds allocated for domestic and foreign demand.

foxnews.com

a year ago

Amid ADHD drug shortage, FDA approves generic version of medication: 'Opportune time'

The FDA approved generic versions of Vyvanse to address ADHD medication shortages, benefiting those 6 and older. Generics aim to match brand-name efficacy and cost less, potentially easing shortages, especially of Adderall. Fourteen companies can now produce generic Vyvanse, also used for binge-eating disorder in adults.

finance.yahoo.com

4 years ago

KemPharm Won FDA Approval, But This Analyst Isn’t Happy

KemPharm's Azstarys, a new ADHD treatment, received FDA approval, potentially bringing significant financial benefits. However, analyst Oren Livnat downgraded KemPharm to Neutral due to concerns over the drug's label and economic uncertainties, despite its promising efficacy and market potential.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.